Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
Would you offer SBRT for a lung lesion adjacent to the heart in a patient receiving bevacizumab?
What CTV expansions do you use for NSCLC with conventional chemoradiation and do you do different expansions based on specific histologies?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
Is there increased risk with lung SBRT in a patient who has a mild asymptomatic pneumothorax in the field after CT-guided needle biopsy?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
What target volumes and expansions would you use for neoadjuvant chemoradiotherapy to a large thymoma with the goal of shrinking the tumor to aid resectability?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
